Navigating the treatment landscape in multiple myeloma: which combinations to use and when?
Author:
Funder
Amgen (Europe) GmbH
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Link
http://link.springer.com/article/10.1007/s00277-018-3546-8/fulltext.html
Reference124 articles.
1. Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C, ESMO Guidelines Committee (2017) Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv52–iv61. https://doi.org/10.1093/annonc/mdx096
2. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5):2516–2520. https://doi.org/10.1182/blood-2007-10-116129
3. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28(5):1122–1128. https://doi.org/10.1038/leu.2013.313
4. Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P (2017) Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 18(10):1327–1337. https://doi.org/10.1016/S1470-2045(17)30578-8
5. Larsen JT, Kumar S (2015) Evolving paradigms in the management of multiple myeloma: novel agents and targeted therapies. Rare Cancers Ther 3:47–68. https://doi.org/10.1007/s40487-015-0009-4
Cited by 60 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A digital twin model for evidence-based clinical decision support in multiple myeloma treatment;Frontiers in Digital Health;2023-12-20
2. Real‐life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study;eJHaem;2023-12-13
3. Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma;Cancer Letters;2023-08
4. Patient perspectives of ‘Watch and Wait’ for chronic haematological cancers: Findings from a qualitative study;European Journal of Oncology Nursing;2023-08
5. Determining optimal combination regimens for patients with multiple myeloma;European Journal of Pharmaceutical Sciences;2023-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3